These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33260446)

  • 1. Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death.
    Choi Y; Yoon HY; Kim J; Yang S; Lee J; Choi JW; Moon Y; Kim J; Lim S; Shim MK; Jeon S; Kwon IC; Kim K
    Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33260446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses.
    Kim J; Choi Y; Yang S; Lee J; Choi J; Moon Y; Kim J; Shim N; Cho H; Shim MK; Jeon S; Lim DK; Yoon HY; Kim K
    Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
    Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
    Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.
    Phung CD; Nguyen HT; Choi JY; Pham TT; Acharya S; Timilshina M; Chang JH; Kim JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
    J Control Release; 2019 Dec; 315():126-138. PubMed ID: 31672625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Formulation and process optimization of doxorubicin-loaded PLGA nanoparticles and its in vitro release].
    Li JL; Zheng CL; Liu JP; Zhu JB
    Yao Xue Xue Bao; 2013 May; 48(5):759-66. PubMed ID: 23888702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Na
    Araste F; Abnous K; Hashemi M; Dehshahri A; Detampel P; Alibolandi M; Ramezani M
    Eur J Pharm Sci; 2020 Feb; 143():105207. PubMed ID: 31870814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy.
    Mosafer J; Abnous K; Tafaghodi M; Mokhtarzadeh A; Ramezani M
    Eur J Pharm Biopharm; 2017 Apr; 113():60-74. PubMed ID: 28012991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A homologous-targeting cGAS-STING agonist multimodally activates dendritic cells for enhanced cancer immunotherapy.
    Wang P; Wang Y; Li H; Wang M; Wang Y; Wang X; Ran L; Xin H; Ma J; Tian G; Gao W; Zhang G
    Acta Biomater; 2024 Mar; 177():400-413. PubMed ID: 38336268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model.
    Chitphet K; Geary SM; Chan CHF; Simons AL; Weiner GJ; Salem AK
    ACS Biomater Sci Eng; 2020 May; 6(5):2659-2667. PubMed ID: 33463284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
    Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
    Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.
    Dai Y; Xing H; Song F; Yang Y; Qiu Z; Lu X; Liu Q; Ren S; Chen X; Li N
    J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photothermal MnO
    Chen Z; Zhang Q; Huang Q; Liu Z; Zeng L; Zhang L; Chen X; Song H; Zhang J
    Int J Pharm; 2022 Apr; 617():121578. PubMed ID: 35176333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy.
    Zhang J; Tao W; Chen Y; Chang D; Wang T; Zhang X; Mei L; Zeng X; Huang L
    J Mater Sci Mater Med; 2015 Apr; 26(4):165. PubMed ID: 25791459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective breast cancer therapy based on palmitic acid-loaded PLGA nanoparticles.
    He Y; de Araújo Júnior RF; Cavalcante RS; Yu Z; Schomann T; Gu Z; Eich C; Cruz LJ
    Biomater Adv; 2023 Feb; 145():213270. PubMed ID: 36603405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
    Liu D; Li K; Gong L; Fu L; Yang D
    Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells.
    Mosafer J; Teymouri M; Abnous K; Tafaghodi M; Ramezani M
    Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():123-133. PubMed ID: 28024568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model.
    Alibolandi M; Sadeghi F; Abnous K; Atyabi F; Ramezani M; Hadizadeh F
    Eur J Pharm Biopharm; 2015 Aug; 94():521-31. PubMed ID: 26170161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of PEG Content on Doxorubicin Release from PLGA-co-PEG Nanoparticles.
    Cardoso MM; Peça IN; Bicho A
    Materials (Basel); 2024 Jul; 17(14):. PubMed ID: 39063836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLGA based particles as "drug reservoir" for antitumor drug delivery: characterization and cytotoxicity studies.
    Chronopoulou L; Domenici F; Giantulli S; Brasili F; D'Errico C; Tsaouli G; Tortorella E; Bordi F; Morrone S; Palocci C; Silvestri I
    Colloids Surf B Biointerfaces; 2019 Aug; 180():495-502. PubMed ID: 31103709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.